A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer

Summary

This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment. During the dose escalation stage, a standard "3+3" design will be used to assess the MTD/ recommended dose for the subsequent studies.

Timeline

Start

2025-03-31

Primary completion

2026-12

Completion

2027-06

Drugs

Indications